Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV)

Abud-Mendoza, Carlos; Cuevas-Orta, Enrique; Santillán-Guerrero, E.; Martínez-Martínez, Marco Ulises; Hernández-Castro, Berenice; Estrada-Capetillo, Lizbeth; González‐Amaro, Roberto; Baranda, Lourdes

doi:10.1007/s00403-012-1258-9

Cited by 19 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the number of lymphocytes averaged approximately 1,000/μl of blood (see Table 2), which is within the range of 490–6,000/μl (median of 2,000/μl) as reported by Park and Han (2012). The percentages of CD3+ lymphocytes (~80%), CD16+/CD56+ cells (~10%), and CD19+ cells (~10%) were also in line with other reports (Abud-Mendoza et al, 2012; Carlson, Speca, Faris, & Patel, 2007; Park & Han, 2012). Regarding the ratio of Th1 to Th2 cells, others have reported ratios from 12.5 (Toldi et al, 2011) to 5.1 (Cseh et al, 2012), while we observed ratios ranging from 3.4 to 9.1 in the present study, depending upon the group.…”

Section: Resultssupporting

confidence: 89%

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

Reich

Lengacher

Kip

et al. 2014

Biological Research For Nursing

View full text Add to dashboard Cite

Researchers focused on patient-centered medicine are increasingly trying to identify baseline factors that predict treatment success. Because the quantity and function of lymphocyte subsets change during stress, we hypothesized that these subsets would serve as stress markers and therefore predict which breast cancer patients would benefit most from mindfulness-based stress reduction (MBSR)-facilitated stress relief. The purpose of this study was to assess whether baseline biomarker levels predicted symptom improvement following an MBSR intervention for breast cancer survivors (MBSR[BC]). This randomized controlled trial involved 41 patients assigned to either an MBSR(BC) intervention group or a no-treatment control group. Biomarkers were assessed at baseline, and symptom change was assessed 6 weeks later. Biomarkers included common lymphocyte subsets in the peripheral blood as well as the ability of T cells to become activated and secrete cytokines in response to stimulation with mitogens. Spearman correlations were used to identify univariate relationships between baseline biomarkers and 6-week improvement of symptoms. Next, backward elimination regression models were used to identify the strongest predictors from the univariate analyses. Multiple baseline biomarkers were significantly positively related to 6-week symptom improvement. The regression models identified B-lymphocytes and interferon-γ as the strongest predictors of gastrointestinal improvement (p < .01), +CD4+CD8 as the strongest predictor of cognitive/psychological (CP) improvement (p = .02), and lymphocytes and interleukin (IL)-4 as the strongest predictors of fatigue improvement (p < .01). These results provide preliminary evidence of the potential to use baseline biomarkers as predictors to identify the patients likely to benefit from this intervention.

show abstract

Section: Resultssupporting

confidence: 89%

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

Reich

Lengacher

Kip

et al. 2014

Biological Research For Nursing

View full text Add to dashboard Cite

show abstract

“…In the univariate analysis, mycophenolic acid was associated with cervical HPV infection, although the association disappeared in the multivariate analysis, possibly because few patients were analyzed. A very recent Mexican study detected low levels of B and NK cells and an enhanced risk of HPV infection in SLE patients receiving mycophenolate mofetil (32). We also found no association between HPV infection and other immunosuppressive therapies, such as azathioprine and methotrexate.…”

Section: And Discussionsupporting

confidence: 58%

Untitled

2013

Clinics

View full text Add to dashboard Cite

OBJECTIVE: To identify the prevalence and factors associated with cervical human papillomavirus infection in women with systemic lupus erythematosus METHODS: This cross-sectional study collected traditional and systemic lupus erythematosus-related disease risk factors, including conventional and biologic therapies. A gynecological evaluation and cervical cytology screen were performed. Human papillomavirus detection and genotyping were undertaken by PCR and linear array assay. RESULTS: A total of 148 patients were included, with a mean age and disease duration of 42.5¡11.8 years and 9.7¡5.3 years, respectively. The prevalence of squamous intraepithelial lesions was 6.8%. The prevalence of human papillomavirus infection was 29%, with human papillomavirus subtype 59 being the most frequent. Patients with human papillomavirus were younger than those without the infection (38.2¡11.2 vs. 44.2¡11.5 years, respectively; p = 0.05), and patients with the virus had higher daily prednisone doses (12.8¡6.8 vs. 9.7¡6.7 mg, respectively; p = 0.01) and cumulative glucocorticoid doses (14.2¡9.8 vs. 9.7¡7.3 g, respectively; p = 0.005) compared with patients without. Patients with human papillomavirus infection more frequently received rituximab than those without (20.9% vs. 8.5%, respectively; p = 0.03). In the multivariate analysis, only the cumulative glucocorticoid dose was associated with human papillomavirus infection. CONCLUSIONS: The cumulative glucocorticoid dose may increase the risk of human papillomavirus infection. Although rituximab administration was more frequent in patients with human papillomavirus infection, no association was found. Screening for human papillomavirus infection is recommended in women with systemic lupus erythematosus. -Cole A, Muñ oz-Guarneros M, Solis-Poblano JC, et al. The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus.

show abstract

“…However, this possible association was lost after adjusting for others factors, such as GC. Similarly, Abud-Mendoza et al (32) found no associations between HPV infection and rituximab in patients with SLE and rheumatoid arthritis. One possible reason why rituximab was not associated with cervical HPV infection might have been that other routes, such as the innate immune response, could have been affected in these patients.…”

Section: Discussionmentioning

confidence: 94%

“…A very recent Mexican study detected low levels of B and NK cells and an enhanced risk of HPV infection in SLE patients receiving mycophenolate mofetil (32). We also found no association between HPV infection and other immunosuppressive therapies, such as azathioprine and methotrexate.…”

Section: Discussionmentioning

confidence: 99%

The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus

Mendoza‐Pinto

Vallejo-Ruíz

Taboada-Cole

et al. 2013

Clinics

View full text Add to dashboard Cite

OBJECTIVE:To identify the prevalence and factors associated with cervical human papillomavirus infection in women with systemic lupus erythematosusMETHODS:This cross-sectional study collected traditional and systemic lupus erythematosus-related disease risk factors, including conventional and biologic therapies. A gynecological evaluation and cervical cytology screen were performed. Human papillomavirus detection and genotyping were undertaken by PCR and linear array assay.RESULTS:A total of 148 patients were included, with a mean age and disease duration of 42.5±11.8 years and 9.7±5.3 years, respectively. The prevalence of squamous intraepithelial lesions was 6.8%. The prevalence of human papillomavirus infection was 29%, with human papillomavirus subtype 59 being the most frequent. Patients with human papillomavirus were younger than those without the infection (38.2±11.2 vs. 44.2±11.5 years, respectively; p = 0.05), and patients with the virus had higher daily prednisone doses (12.8±6.8 vs. 9.7±6.7 mg, respectively; p = 0.01) and cumulative glucocorticoid doses (14.2±9.8 vs. 9.7±7.3 g, respectively; p = 0.005) compared with patients without. Patients with human papillomavirus infection more frequently received rituximab than those without (20.9% vs. 8.5%, respectively; p = 0.03). In the multivariate analysis, only the cumulative glucocorticoid dose was associated with human papillomavirus infection.CONCLUSIONS:The cumulative glucocorticoid dose may increase the risk of human papillomavirus infection. Although rituximab administration was more frequent in patients with human papillomavirus infection, no association was found. Screening for human papillomavirus infection is recommended in women with systemic lupus erythematosus.

show abstract

Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV)

Cited by 19 publications

References 26 publications

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

Baseline Immune Biomarkers as Predictors of MBSR(BC) Treatment Success in Off-Treatment Breast Cancer Patients

Untitled

The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus

Contact Info

Product

Resources

About